An interventional study of Biospecimen Collection and Excision in Clinical Stage IA Cutaneous Melanoma AJCC v8 and Clinical Stage IB Cutaneous Melanoma AJCC v8, sponsored by OHSU Knight Cancer Institute. Suspended at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by OHSU Knight Cancer Institute · Not applicable, Interventional, and Treatment
Pending coordinating center transition
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Melanoma by OHSU Knight Cancer Institute — 2 open to participants now, 4 under way, none of them phase 3. Melanoma · OHSU Knight Cancer Institute.
Among the 11 studies in Melanoma by OHSU Knight Cancer Institute, this one is one of 2 that started in 2024, is one of 6 with no phase, and was the 9th registered.
3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.
Browse Melanoma studies →2 of the 11 studies in Melanoma by OHSU Knight Cancer Institute are open now, in 1 country. Recruiting first, the newest first:
OHSU Knight Cancer Institute · Sites in United States
Ages 18+
OHSU Knight Cancer Institute · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 40 across 2,652 interventional studies indexed under Melanoma.
Median enrollment 102 across the 8 interventional studies, 24 across the 3 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
OHSU Knight Cancer Institute is the lead sponsor of 243 studies on the registry; 42 are open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 15 (56%) have results posted.
1 of the studies in Melanoma by OHSU Knight Cancer Institute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04611568OHSU Knight Cancer InstituteWar on Melanoma™ Public Health & Education Campaign | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Melanoma by OHSU Knight Cancer Institute, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial compares the effect of a narrow surgical excision (removal) to a wide excision for the treatment of adults with invasive cutaneous melanoma. Currently the standard of care is to take wide margins (boarder of healthy tissue surrounding the melanoma) when removing melanoma. Narrow margin excision removes a smaller amount of healthy tissue when surgically removing the melanoma. Narrow margin excision may be effective in removing the melanoma while also reducing surgical complications and improving quality of life for adults with invasive cutaneous melanoma.
PRIMARY OBJECTIVE:
I. To compare the 3-year local recurrence-free survival rates (RFS) in melanoma patients treated with narrow excision versus (vs) wide excision.
SECONDARY OBJECTIVES:
I. To measure the 3-, 5-year Regional (nodal) disease-free survival (DFS) in melanoma patients treated with active nodal surveillance.
II. To compare 5-year local recurrence-free survival in patients treated with narrow vs wide excision.
III. To compare 5-year Melanoma Specific Survival (MSS) in patients treated with narrow vs wide excision.
IV. To compare the quality of life in patients treated with narrow vs wide excision.
V. To compare surgical complication rates in patients treated with narrow vs wide excision.
VI. To compare the frequency of complex reconstruction in patients treated with narrow vs wide excision.
VII. To compare the final defect size in patients treated with narrow vs wide excision.
VIII. To compare the number of operative/procedure days required to achieve negative margins.
EXPLORATORY OBJECTIVE:
I. To measure the T- and B-cell repertoires in patients with melanoma over time.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients undergo narrow margin excision on study. Patients may optionally undergo blood sample collection throughout the study.
ARM II: Patients undergo wide margin excision on study. Patients may optionally undergo blood sample collection throughout the study.
After completion of study treatment, patients are followed up at 1 week, 3, 6, 12, 36, 48, and 60 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must have one of the following:
AJCC 8th Ed Clinical Stage IB melanoma
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergo narrow margin excision on study. Patients may optionally undergo blood sample collection throughout the study.
Procedure: Biospecimen Collection · Procedure: Excision · Other: Survey Administration
Patients undergo wide margin excision on study. Patients may optionally undergo blood sample collection throughout the study.
Procedure: Biospecimen Collection · Procedure: Excision · Other: Survey Administration
Undergo blood sample collection
Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection
Undergo narrow margin excision
Also known as: Abscission, Extirpation, Surgical Removal
Undergo wide margin excision
Also known as: Abscission, Extirpation, Surgical Removal
Ancillary studies
Local recurrence rate
Defined as average rate at which cancer returns to same location as the original tumor.
Time frame: From randomization to end of year 3
Regional (nodal) disease-free survival
Average number of participants who are experiencing regional disease-free survival at 3 and 5 years.
Time frame: From randomization to end of year 5
Local recurrence-free survival
The average length of time (in months) from the date of randomization to local recurrence.
Time frame: From randomization to end of year 5
Melanoma-specific survival
The average length of time (in months) from date of randomization to death.
Time frame: From randomization to end of year 5
Postoperative pain
Measured by numeric rating scale (0-10).
Time frame: Up to 30 days after surgery
Quality of life
Quality of life score as measured by either the Facial Appearance, Quality of Life, and Experience Questionnaire (FACE-Q) score in patients with melanoma on the face or the Functional Assessment of Cancer Therapy - Melanoma (FACT-M) score for patients with melanoma elsewhere on the body. FACT-M is a tool for measuring health-related quality of life in patients with melanoma. It has 51 items, Scores range from 0 to 120 with higher score indicating better quality of life (QOL). FACE-Q includes 5 independently functioning scales and 2 checklists that measure outcomes important to patients from their perspective.
Time frame: Up to postoperative day 90
Surgical complication rate
Defined as the proportion of patients experiencing a surgical complication.
Time frame: Up to postoperative day 90
Frequency of complex reconstruction
Defined as the proportion of patients receiving any flap or graft reconstruction.
Time frame: Immediately after surgery
Defect size
The size of the defect is measured as the greatest dimension of the final wound multiplied by the dimension perpendicular to the greatest dimension.
Time frame: Immediately after surgery
Number of operative/procedure days
Will compare the number of operative/procedure days required to achieve negative margins. Will be reported and compared separately (Mohs surgery, narrow excision with permanent sections, wide excision with permanent sections, and slow Mohs).
Time frame: Up to postoperative day 90
Started Dec 2024 (actual). Primary completion is estimated for Dec 2027, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
Pending coordinating center transition
Pending coordinating center transition
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is suspended, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
OHSU Knight Cancer Institute →